TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31709982

Group type: EXPERIMENTAL
Intervention: VDD pacing (automated, enhanced accelerometer-based algorithm)
Number of subjects: 75

Group type: COMPARATOR
Intervention: VVI-50 pacing (control)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: VDD pacing
Number of subjects: 75
Study: 31710189

Group type: EXPERIMENTAL
Intervention: Vaginal sildenafil (suppository-100 mg/daily)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Vaginal placebo/sildenafil (suppository-100 mg/daily)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Vaginal placebo (suppository)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 66
Study: 31710193

Group type: EXPERIMENTAL
Intervention: Zinc sulfate supplementation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (healthy men)
Number of subjects: 60
Study: 31710528

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 31710684

Group type: EXPERIMENTAL
Intervention: CYP2D6 genotype classification (gNMs-F, gNMs-S, gIMs, gPMs)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Therapies and side effects experienced by patients
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Evaluation of metabolic activity
Number of subjects: 100
Study: 31710793

Group type: COMPARATOR
Intervention: Proposed COPDGene criteria for diagnosing COPD
Number of subjects: 8784

Group type: EXPERIMENTAL
Intervention: Expanded criteria for COPD diagnosis
Number of subjects: 8784

Group type: EXPERIMENTAL
Intervention: Integrated approach using environmental exposure, clinical symptoms, CT imaging and spirometric criteria
Number of subjects: 8784
Study: 31710864

Group type: EXPERIMENTAL
Intervention: Lenvatinib 24 mg/day
Number of subjects: 25
Study: 31710859

Group type: EXPERIMENTAL
Intervention: Mood Disorder Questionnaire (MDQ) screening for bipolar disorder
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: Current psychiatric care
Number of subjects: 574
Study: 31710876

Group type: EXPERIMENTAL
Intervention: Insomnia and high rumination
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Insomnia alone
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: High rumination alone
Number of subjects: 267

Group type: COMPARATOR
Intervention: Good-sleeping women with low rumination
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Depressed women
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Suicidal ideation
Number of subjects: 267
Study: 31711108

Group type: EXPERIMENTAL
Intervention: Intact casein (C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrolyzed casein (HC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Free amino acid mixture (A)
Number of subjects: 0
Study: 31711111

Group type: EXPERIMENTAL
Intervention: 3 Wishes Project (3WP) intervention
Number of subjects: 730
Study: 31711170

Group type: EXPERIMENTAL
Intervention: Breakfast consumers (consumed breakfast ≥230 kcal between 04:00 and 10:00)
Number of subjects: 472

Group type: COMPARATOR
Intervention: Breakfast skippers (did not consume breakfast ≥230 kcal)
Number of subjects: 472
Study: 31711433

Group type: EXPERIMENTAL
Intervention: Condomless anal intercourse (CAI) reported with ≥1 of their last three partners
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Sex with casual partners in homes
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Sex with casual partners in hotels
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Sex with anonymous partners in saunas/Internet cabins
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Sex with anonymous partners in public spaces
Number of subjects: 447

Group type: COMPARATOR
Intervention: CAI in hotels compared to homes
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Marijuana use before sex at home
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Partner alcohol use before sex in saunas/Internet cabins
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Partner alcohol use before sex in public spaces
Number of subjects: 447
Study: 31712075

Group type: EXPERIMENTAL
Intervention: Management of pain with opioid analgesics
Number of subjects: 1612

Group type: EXPERIMENTAL
Intervention: Cholecystectomy at hospital admission
Number of subjects: 1612

Group type: COMPARATOR
Intervention: Severe acute pancreatitis outcomes
Number of subjects: 1612

Group type: COMPARATOR
Intervention: Etiology of acute pancreatitis
Number of subjects: 1612

Group type: COMPARATOR
Intervention: Demographics and comorbid conditions
Number of subjects: 1612

Group type: COMPARATOR
Intervention: Classification of disease severity
Number of subjects: 1612
Study: 31712344

Group type: EXPERIMENTAL
Intervention: Prehospital delay
Number of subjects: 7312

Group type: EXPERIMENTAL
Intervention: First ECG delay
Number of subjects: 7312

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy delay
Number of subjects: 7312

Group type: EXPERIMENTAL
Intervention: In-hospital delay
Number of subjects: 7312
Study: 31712349

Group type: EXPERIMENTAL
Intervention: Antineoplastic drugs (AD) exposure in nursing staff
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-questionnaire detailing professional activities
Number of subjects: 0
Study: 31712445

Group type: EXPERIMENTAL
Intervention: CRC-associated microbiota
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls' microbiota
Number of subjects: 0
Study: 31712720

Group type: EXPERIMENTAL
Intervention: Genome-wide association study (GWAS) of panic disorder
Number of subjects: 2248

Group type: EXPERIMENTAL
Intervention: Linkage disequilibrium (LD) score regression analysis
Number of subjects: 2248

Group type: EXPERIMENTAL
Intervention: 255 single-nucleotide polymorphisms (SNPs)
Number of subjects: 2248
Study: 31712813

Group type: EXPERIMENTAL
Intervention: Gentamicin 360 mg intramuscular dose
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Gentamicin Cmax and MIC measurements
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Creatinine measurement
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Headache incidence
Number of subjects: 10
Study: 31713013

Group type: EXPERIMENTAL
Intervention: Continuous monitoring of vital signs
Number of subjects: 30

Group type: COMPARATOR
Intervention: Routine ward rounds
Number of subjects: 30
Study: 31713056

Group type: EXPERIMENTAL
Intervention: Structured daily hip exercise regimen (extension and external rotation)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 8
Study: 31713130

Group type: EXPERIMENTAL
Intervention: Dalbavancin
Number of subjects: 43

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 43
Study: 31713160

Group type: EXPERIMENTAL
Intervention: Linagliptin monotherapy
Number of subjects: 2235
Study: 31713310

Group type: EXPERIMENTAL
Intervention: GORE® Carotid Stent (GCS)
Number of subjects: 312
Study: 31714428

Group type: EXPERIMENTAL
Intervention: Duration of antiretroviral therapy use (particularly related to protease inhibitor use)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Duration of HIV
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: CD4 T-cell count
Number of subjects: 18

Group type: COMPARATOR
Intervention: HIV viral load
Number of subjects: 18
Study: 31714987

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 30
Study: 31715023

Group type: EXPERIMENTAL
Intervention: Post-operative patients who developed early POCD (n=24, 19.4%)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Non-POCD patients
Number of subjects: 124
Study: 31717747

Group type: EXPERIMENTAL
Intervention: Liquid biopsy using CellSearch
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Liquid biopsy combining several biomarkers
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Combined CTC and exosome detection
Number of subjects: 22
Study: 31718316

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 31718534

Group type: EXPERIMENTAL
Intervention: PCV13 immunization
Number of subjects: 0

Group type: COMPARATOR
Intervention: PPV23 immunization
Number of subjects: 0
Study: 31718666

Group type: EXPERIMENTAL
Intervention: OCTA (Optical Coherence Tomography Angiography)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Intravital capillaroscopy
Number of subjects: 140

Group type: COMPARATOR
Intervention: OCTA
Number of subjects: 140

Group type: COMPARATOR
Intervention: LEPCs function
Number of subjects: 140
Study: 31718676

Group type: EXPERIMENTAL
Intervention: Sputum AcPGP concentrations
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Plasma AcPGP concentrations
Number of subjects: 182
Study: 31719001

Group type: EXPERIMENTAL
Intervention: MPI
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: CCTA
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Prediction models
Number of subjects: 49
Study: 31719030

Group type: EXPERIMENTAL
Intervention: Fitbit Plus app enhanced with a face-to-face LifeSteps session
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 60
Study: 31719069

Group type: EXPERIMENTAL
Intervention: Late chronotype
Number of subjects: 2247

Group type: COMPARATOR
Intervention: Early chronotype
Number of subjects: 2247

Group type: EXPERIMENTAL
Intervention: All chronotypes (categorical variable)
Number of subjects: 2247

Group type: EXPERIMENTAL
Intervention: All chronotypes (continuous variable)
Number of subjects: 2247
Study: 31719077

Group type: EXPERIMENTAL
Intervention: Full dose of opioids with NSAIDs
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: 50% overall reduction in opioid dosage, dose-extending placebos and NSAIDs
Number of subjects: 159

Group type: COMPARATOR
Intervention: NSAIDs and placebos
Number of subjects: 159
Study: 31719258

Group type: EXPERIMENTAL
Intervention: Highest quartile of serum cystatin C levels
Number of subjects: 638

Group type: COMPARATOR
Intervention: Lowest quartile of serum cystatin C levels
Number of subjects: 638
Study: 31719684

Group type: EXPERIMENTAL
Intervention: CNS metastasis-free survival (CNSM-FS)
Number of subjects: 16703

Group type: EXPERIMENTAL
Intervention: Overall survival (OS) after CNS metastasis diagnosis
Number of subjects: 16703
Study: 31720000

Group type: EXPERIMENTAL
Intervention: Breath tests
Number of subjects: 50
Study: 31720254

Group type: EXPERIMENTAL
Intervention: Flaxseed enriched yogurt (200 g 2.5% fat yogurt containing 30-g flaxseed)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Flaxseed enriched yogurt
Number of subjects: 57

Group type: COMPARATOR
Intervention: Plain yogurt (control)
Number of subjects: 57
Study: 31720293

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI; Trelegy) delivered by the ELLIPTA inhaler, once daily for 24 weeks
Number of subjects: 0
Study: 31720962

Group type: EXPERIMENTAL
Intervention: CKD discussions during routine visits
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: CKD awareness assessment
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Follow-up CKD awareness
Number of subjects: 48
Study: 31721017

Group type: EXPERIMENTAL
Intervention: Spebrutinib 375 mg/day
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 31721213

Group type: EXPERIMENTAL
Intervention: Bed rest
Number of subjects: 0
Study: 31721246

Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL) monotherapy withdrawal over ~6 months
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL) monotherapy withdrawal
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Biopsy gene signature
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Biopsy staining at study end
Number of subjects: 15
Study: 31721643

Group type: EXPERIMENTAL
Intervention: Atezolizumab 1,200 mg and Bevacizumab 15 mg/kg intravenously every 3 weeks
Number of subjects: 60
Study: 31722205

Group type: EXPERIMENTAL
Intervention: Interferon-α
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased IFNAR1 surface expression
Number of subjects: 0
Study: 31722671

Group type: EXPERIMENTAL
Intervention: Epley maneuver
Number of subjects: 134
Study: 31722680

Group type: EXPERIMENTAL
Intervention: Patient-centered pharmacist care (comprehensive review at months 3 and 5)
Number of subjects: 72
Study: 31722685

Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasound (POCUS) training for ETT localization
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-of-care methods for ETT localization
Number of subjects: 0
Study: 31722736

Group type: EXPERIMENTAL
Intervention: MDSCs obtained at and beyond 14 days post-sepsis
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: MDSCs obtained at various intervals over 6 weeks
Number of subjects: 267
Study: 31722951

Group type: EXPERIMENTAL
Intervention: Manual therapy applied to craniomandibular structures, with four weekly sessions.
Number of subjects: 100
Study: 31723056

Group type: EXPERIMENTAL
Intervention: Labyrinth Devices Multichannel Vestibular Implant System vestibular implant
Number of subjects: 4
Study: 31723443

Group type: EXPERIMENTAL
Intervention: Arabic linguistic version of the Overactive Bladder Symptoms Score questionnaire
Number of subjects: 0
Study: 31723723

Group type: EXPERIMENTAL
Intervention: Pregnant women in the second trimester
Number of subjects: 0

Group type: COMPARATOR
Intervention: Men
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pregnant women during pregnancy and 6 months postpartum
Number of subjects: 0
Study: 31723767

Group type: EXPERIMENTAL
Intervention: Idelalisib in combination with Rituximab (IR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Idelalisib in combination with Bendamustine (IB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Idelalisib in combination with both Rituximab and Bendamustine (IBR)
Number of subjects: 0
Study: 31723837

Group type: EXPERIMENTAL
Intervention: MRI assessment of iron load
Number of subjects: 243
Study: 31724050

Group type: EXPERIMENTAL
Intervention: Moderate to Severe (M/S) influenza
Number of subjects: 1478

Group type: COMPARATOR
Intervention: Mild disease
Number of subjects: 1478
Study: 31724339

Group type: EXPERIMENTAL
Intervention: FAST
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: FAST + GHA
Number of subjects: 9

Group type: COMPARATOR
Intervention: CTRL
Number of subjects: 9
Study: 31724813

Group type: EXPERIMENTAL
Intervention: Talazoparib (600 µg/m) in combination with low-dose temozolomide (TMZ)
Number of subjects: 40
Study: 31725015

Group type: EXPERIMENTAL
Intervention: BET inhibitor apabetalone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31725157

Group type: EXPERIMENTAL
Intervention: Sustainable Diet Index (SDI) Q1 (lowest sustainability)
Number of subjects: 15626

Group type: COMPARATOR
Intervention: Sustainable Diet Index (SDI) Q5 (highest sustainability)
Number of subjects: 15626
Study: 31725351

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks for up to 2 years
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 124
Study: 31725442

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 31725459

Group type: EXPERIMENTAL
Intervention: Antiviral therapy for 78 weeks
Number of subjects: 683
Study: 31725531

Group type: EXPERIMENTAL
Intervention: Extracorporeal membrane oxygenation support
Number of subjects: 24
Study: 31726319

Group type: EXPERIMENTAL
Intervention: Blood pressure monitoring in patients with orthostatic hypotension (OH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood pressure variability assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality of life assessment
Number of subjects: 0
Study: 31726422

Group type: EXPERIMENTAL
Intervention: Proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i)
Number of subjects: 5006

Group type: COMPARATOR
Intervention: High-intensity statins
Number of subjects: 5006

Group type: COMPARATOR
Intervention: Ezetimibe
Number of subjects: 5006
Study: 31726452

Group type: EXPERIMENTAL
Intervention: BoNT-A injection
Number of subjects: 100
Study: 31727019

Group type: EXPERIMENTAL
Intervention: Unilateral elective nodal irradiation (ENI) selected by lymph drainage mapping using SPECT/CT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bilateral elective nodal irradiation (ENI)
Number of subjects: 0
Study: 31727075

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 79
Study: 31727113

Group type: EXPERIMENTAL
Intervention: Trastuzumab-emtansine (T-DM1)
Number of subjects: 154
Study: 31727136

Group type: EXPERIMENTAL
Intervention: suPAR pre-OP
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: suPAR 3-5 days post-OP
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: suPAR 6-11 days post-OP
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: CRP pre-OP
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: CRP 6-11 days post-OP
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Combination of suPAR and CRP
Number of subjects: 36
Study: 31727169

Group type: EXPERIMENTAL
Intervention: Amyloid positron emission tomography (PET) imaging
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Neuropathological and biochemical examination of Aβ pathology
Number of subjects: 271
Study: 31727669

Group type: EXPERIMENTAL
Intervention: Sedation/analgesia (SA)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sufentanil and midazolam
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: SA premedication
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: SA
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 40
Study: 31727685

Group type: EXPERIMENTAL
Intervention: Plasma linoleic acid (LA)
Number of subjects: 3257

Group type: EXPERIMENTAL
Intervention: Dietary linoleic acid (LA)
Number of subjects: 3257
Study: 31728032

Group type: EXPERIMENTAL
Intervention: High Atherogenic Index of Plasma (AIP)
Number of subjects: 2485

Group type: EXPERIMENTAL
Intervention: Incident AIP group
Number of subjects: 2485

Group type: COMPARATOR
Intervention: Normal AIP at baseline and elevated AIP in 2013
Number of subjects: 2485
Study: 31728500

Group type: EXPERIMENTAL
Intervention: Dietary pulses with or without other legumes
Number of subjects: 83284
Study: 31728837

Group type: EXPERIMENTAL
Intervention: INHD
Number of subjects: 67

Group type: COMPARATOR
Intervention: CHD (Control)
Number of subjects: 67
Study: 31729626

Group type: EXPERIMENTAL
Intervention: Peficitinib (150 mg single oral dose)
Number of subjects: 0
Study: 31729979

Group type: EXPERIMENTAL
Intervention: Prediabetes (HbA1c between 5.7 and 6.4%)
Number of subjects: 6688

Group type: EXPERIMENTAL
Intervention: Prediabetes (HbA1c between 5.7 and 6.4%) with 3 or more cardiovascular risk factors
Number of subjects: 6688

Group type: EXPERIMENTAL
Intervention: Males with prediabetes
Number of subjects: 6688
Study: 31730043

Group type: EXPERIMENTAL
Intervention: M-Cubed (M3) app for a period of three months
Number of subjects: 1229

Group type: COMPARATOR
Intervention: Waitlist-control (delayed access to M3 app)
Number of subjects: 1229
Study: 31730164

Group type: EXPERIMENTAL
Intervention: IV administration of ertapenem (1 g once daily)
Number of subjects: 26
Study: 31730380

Group type: EXPERIMENTAL
Intervention: Young women with breast cancer (≤ 40 years)
Number of subjects: 2888

Group type: COMPARATOR
Intervention: Older women with breast cancer (> 40 years)
Number of subjects: 2888
Study: 31730450

Group type: EXPERIMENTAL
Intervention: HIV prevention and care services access
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Community-engagement strategies and gender-affirming research methods
Number of subjects: 186
Study: 31730497

Group type: EXPERIMENTAL
Intervention: Conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) including methotrexate (MTX)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Presence of erosions at baseline
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: HAQ-DI ≥1 at inclusion and active smoking
Number of subjects: 172
Study: 31730687

Group type: EXPERIMENTAL
Intervention: rurioctocog alfa pegol (9 patients on prophylaxis, 1 patient on-demand)
Number of subjects: 10
Study: 31731085

Group type: EXPERIMENTAL
Intervention: Obese children
Number of subjects: 1246

Group type: EXPERIMENTAL
Intervention: Increase in BMI
Number of subjects: 1246

Group type: EXPERIMENTAL
Intervention: Per stage increase of CRF
Number of subjects: 1246

Group type: EXPERIMENTAL
Intervention: Higher CRF in obese children
Number of subjects: 1246
Study: 31732519

Group type: EXPERIMENTAL
Intervention: Humanized anti-CD19 scFv CAR-T (hCAR-T)
Number of subjects: 10
Study: 31732566

Group type: EXPERIMENTAL
Intervention: Apathy rating scores
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: β-amyloidopathy
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Regional brain findings
Number of subjects: 64
Study: 31732655

Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (PCI)
Number of subjects: 232353

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 232353

Group type: EXPERIMENTAL
Intervention: Increased prescription of P2Y
Number of subjects: 232353
Study: 31732715

Group type: EXPERIMENTAL
Intervention: Ketamine infusion (0.5 mg/kg) over 40 minutes
Number of subjects: 39
Study: 31733180

Group type: EXPERIMENTAL
Intervention: Rivaroxaban at a dose of 10 mg daily (with aspirin at a dose of 75 to 100 mg daily for the first 3 months)
Number of subjects: 1644

Group type: COMPARATOR
Intervention: Antiplatelet group (aspirin at a dose of 75 to 100 mg daily with clopidogrel at a dose of 75 mg daily for the first 3 months)
Number of subjects: 1644
Study: 31734214

Group type: EXPERIMENTAL
Intervention: High-risk plaque (HRP) lesions with ≥2 features of positive remodeling, spotty calcification, or low-attenuation plaque.
Number of subjects: 1297

Group type: COMPARATOR
Intervention: Non-HRP lesions.
Number of subjects: 1297

Group type: EXPERIMENTAL
Intervention: Baseline total PAV and %DS.
Number of subjects: 1297

Group type: EXPERIMENTAL
Intervention: Presence of HRP.
Number of subjects: 1297
Study: 31734525

Group type: EXPERIMENTAL
Intervention: NPSR1 T risk allele carriers
Number of subjects: 121

Group type: COMPARATOR
Intervention: Healthy controls (HC) with A/A genotype
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Patients with one or two T alleles
Number of subjects: 121
Study: 31734620

Group type: EXPERIMENTAL
Intervention: Objective sleep continuity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subjective sleep disturbance
Number of subjects: 0
Study: 31734695

Group type: EXPERIMENTAL
Intervention: Investigational assays for N. gonorrhoeae and C. trachomatis detection
Number of subjects: 2598
Study: 31734781

Group type: COMPARATOR
Intervention: NaF PET/CT-derived values
Number of subjects: 136

Group type: COMPARATOR
Intervention: Framingham risk score patterns
Number of subjects: 136